Viking Therapeutics continued producing eye-catching obesity data with its dual GLP-1/GIP agonist VK2735 at the ObesityWeek 2024 meeting in San Antonio, with its oral formulation showing class-leading weight loss results in updated findings from a Phase I multiple-ascending-dose (MAD) study. Meanwhile, CinFina Pharma reported weight reduction and tolerability for a pair of Phase I obesity candidates with next-generation mechanisms of action.
Viking Excites With Latest Oral VK2735 Weight Loss Data
CinFina Advances Next-Generation Obesity Drugs
Viking’s dual GLP-1/GIP agonist VK2735 continues to make headlines for strong efficacy and tolerability with oral and injectable formulations. CinFina reports progress with two new MOAs.
